文献速递消化系统肿瘤

早期ctDNA与免疫检查点抑制剂治疗转移性结直肠癌的生存:SAMCO-PRODIGE 54随机临床试验的二次分析

Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

该研究为SAMCO-PRODIGE 54随机临床试验的预设二次分析,评估肿瘤特异性甲基化标志物检测的ctDNA在dMMR/MSI-H转移性结直肠癌接受阿维鲁单抗或标准化疗患者中的预后与预测作用。结果显示基线ctDNA阳性或浓度与临床结局无关,而治疗1个月后ctDNA变化与PFS和OS显著相关,尤其在阿维鲁单抗组中更为明显。

要点

  • 基线ctDNA阳性或浓度与PFS和OS无关。
  • ctDNA变化(以中位值为界)与PFS(HR 2.98)和OS(HR 3.61)显著相关。
  • 阿维鲁单抗组中ctDNA无应答与疾病进展和死亡风险增加相关(HR 7.27)。

核心结论

  • 治疗1个月后ctDNA变化可预测dMMR/MSI-H转移性结直肠癌接受ICIs治疗的长期结局。

研究设计与样本

  • SAMCO-PRODIGE 54随机临床试验的预设二次分析,评估dMMR/MSI-H转移性结直肠癌二线接受阿维鲁单抗或标准化疗(联合或不联合靶向药物)患者的ctDNA预后作用。
  • 血浆样本于2018年4月至2021年4月在法国49个中心前瞻性采集,基线(V1)和治疗开始后1个月(V2)各采集一次。
  • 采用数字微滴聚合酶链反应扩增亚硫酸氢盐转化的游离DNA中WIF1和NPY基因以定量ctDNA水平。
  • 预测分析纳入99例有V1血浆样本可评估ctDNA的患者(平均[SD]年龄66[13]岁;女性51例[51.5%]),其中74例有V2样本可评估ctDNA变化。
  • 数据分析于2024年10月1日至11月1日进行。

主要发现

  • 在99例有V1血浆样本的患者中,基线ctDNA阳性或浓度与临床结局无关。
  • ctDNA变化(以中位值为界)与PFS显著相关(HR 2.98;95%CI 1.77-5.01;P<.001),与OS显著相关(HR 3.61;95%CI 1.81-7.17;P<.001)。
  • 阿维鲁单抗组中ctDNA变化与PFS相关(HR 4.22;95%CI 1.77-10.1;P=.001),与OS相关(HR 17.40;95%CI 3.82-79.70;P<.001);化疗组中与PFS相关(HR 2.09;95%CI 1.03-4.21;P=.04),与OS无统计学显著关联(HR 1.51;95%CI 0.61-3.72;P=.38)。
  • 在ctDNA应答良好者中,阿维鲁单抗较化疗改善PFS(HR 0.33;95%CI 0.14-0.77;log-rank P=.008);在应答不佳者中未见改善(HR 1.32;95%CI 0.67-2.62;log-rank P=.42)。
  • 多变量分析中,ctDNA无应答与阿维鲁单抗组疾病进展和死亡风险增加相关(HR 7.27;95%CI 2.23-23.7;P=.001),化疗组无显著关联(HR 1.61;95%CI 0.66-3.93;P=.30)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint inhibitors (ICIs) have dramatically transformed the therapeutic landscape of deficient mismatch repair/microsatellite unstable-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC); however, ICI use is challenged by primary resistance and timing of discontinuation. Whether circulating tumor DNA (ctDNA) may be predictive of progression-free survival (PFS) and overall survival (OS) in this treatment context remains unknown. OBJECTIVE: To assess the prognostic and predictive role of ctDNA, detected by tumor-specific methylation markers, in patients with dMMR/MSI-H mCRC treated with ICIs. DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of the SAMCO-PRODIGE 54 randomized clinical trial evaluated ctDNA in patients with dMMR/MSI-H mCRC treated with avelumab or standard chemotherapy, with or without a targeted agent in the second-line setting, to assess its prognostic role. Plasma samples were obtained prospectively for ctDNA analysis, and digital droplet polymerase chain reaction amplification of bisulfite-converted cell-free DNA (cfDNA) for WIF1 and NPY genes was used to quantify ctDNA levels. These samples were collected from April 2018 to April 2021 at 49 sites in France at baseline (V1) and 1-month posttreatment initiation (V2) during. Data analyses were performed from October 1 to November 1, 2024. INTERVENTION: Avelumab or standard chemotherapy with or without targeted agents. MAIN OUTCOMES AND MEASURES: PFS and OS according to baseline ctDNA positivity or concentration, and early ctDNA variation (ΔctDNA = [V1-V2] ÷ V1). RESULTS: The predictive analysis included 99 patients (mean [SD] age, 66 [13] years; 51 female [51.5%]) with plasma samples available for ctDNA assessment at V1, of which 74 had samples available also at V2 for Change in ctDNA assessment. In the 99 patients with available V1 plasma samples, baseline ctDNA positivity or concentration were not associated with clinical outcomes. Change in ctDNA (cutoff at median value) was significantly associated with both PFS (hazard ratio [HR], 2.98; 95% CI, 1.77-5.01; P < .001) and OS (HR, 3.61; 95% CI, 1.81-7.17; P < .001). This association was evident in patients treated with avelumab (PFS HR, 4.22; 95% CI, 1.77-10.1; P = .001; OS HR, 17.40; 95% CI, 3.82-79.70; P < .001) than in those receiving chemotherapy (PFS HR, 2.09; 95% CI, 1.03-4.21; P = .04; OS HR, 1.51; 95% CI, 0.61-3.72; P = .38). Avelumab (vs chemotherapy) improved PFS in favorable ctDNA responders (HR, 0.33; 95% CI, 0.14-0.77; log-rank P = .008) but not in poor responders (HR, 1.32; 95% CI, 0.67-2.62; log-rank P = .42) Combined ctDNA response and RECIST, version 1.1, assessment accurately predicted long-term OS. In the multivariable analysis, lack of ctDNA response was associated with an increased risk of disease progression and death in the avelumab group (HR, 7.27; 95% CI, 2.23-23.7; P = .001) but not in the chemotherapy group (HR, 1.61; 95% CI, 0.66-3.93; P = .30). CONCLUSIONS: The findings of this secondary analysis of an RCT found that change in ctDNA at 1-month posttreatment can predict long-term outcomes in patients with dMMR/MSI-H mCRC treated with ICIs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03186326.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Taïeb J, Sullo FG, Lecanu A, et al. Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40531517. doi:10.1001/jamaoncol.2025.1646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。